About

Publications While At HealthPartners

selected publications

Journal Article

Glycemic outcomes persist for up to 2 years in very young children with the Omnipod(®) 5 Automated Insulin Delivery System. 

Diabetes Technology & Therapeutics. 2024

Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. 

Diabetes, Obesity & Metabolism. 2024

Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes. 

Diabetes Technology & Therapeutics. 2024

Assessing time in range with postprandial glucose-focused titration of ultra rapid lispro (URLi) in people with type 1 diabetes. 

Diabetes Therapy. 2023

Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. 

Diabetes Technology & Therapeutics. 2023

Safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. 

Diabetes care. 2023

Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2023

Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2022

How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod® 5 System. 

Diabetes Research and Clinical Practice. 2022

Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in adolescents and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2022

Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. 

Diabetes care. 2022

First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2021

Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. 

Diabetes care. 2021

Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. 

Diabetes Technology & Therapeutics. 2021

Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. 

JAMA. 2020

Ultra-rapid lispro improves postprandial glucose control and time in range in type 1 diabetes compared to lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. 

Diabetes Technology & Therapeutics. 2020

Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: a multicentre, randomized controlled trial using continuous glucose monitoring. 

Diabetes, Obesity & Metabolism. 2019

Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. 

The lancet. Diabetes & endocrinology. 2017

Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). 

Diabetes care. 2017

Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2017

REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. 

Diabetes care. 2017

Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. 

JAMA. 2016

Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. 

JAMA. 2015

Predictors of hypoglycemia in the ASPIRE In-Home study and effects of automatic suspension of insulin delivery. 

Journal of Diabetes Science and Technology. 2015

Response to comment on Wong et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. 

Diabetes care. 2015

Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. 

Diabetes care. 2014

ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. 

Journal of Diabetes Science and Technology. 2013

Threshold-based insulin-pump interruption for reduction of hypoglycemia. 

New England Journal of Medicine. 2013

Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study. 

Diabetes Technology & Therapeutics. 2012

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. 

Diabetes care. 2005

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. 

Diabetes care. 2005

Conference Poster

Improved glycemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes [poster]

2018

Pivotal trial of a hybrid closed-loop system in type 1 diabetes (T1D) [poster]

2016

Abstract

First home evaluation of the Omnipod Horizon automated glucose control system at specific glucose targets in children with type 1 diabetes [abstract]. 

Diabetes. 2020

Safety and glycemic outcomes of the MiniMed advanced hybrid closed-loop (AHCL) system in subjects with T1D [abstract]. 

Diabetes. 2020

Ultra-Rapid Lispro (URLi) demonstrates similar time-in-target range to Humalog with the Medtronic MiniMed 670G Hybrid Closed-Loop System [abstract]. 

Diabetes. 2020

Double-blind mealtime faster-acting insulin aspart vs. insulin aspart in basal-bolus improves glycemic control in T1D: the Onset 1 Trial [abstract #293-OR]. 

Diabetes. 2016

Contact

full name

B. W. Bode

Quick Info

 

Collaboration

Co-author network

Map of science